Appeal No. 1999-2200 Application No. 08/896,063 Patent No. 5,643,785 (‘785) are patentable75. Claims 1, 4 and 8 of the ‘785 patent read as follows: 1. An isolated polynucleotide that encodes an AMPA-binding human GluR4B receptor having the sequence of amino acid residues 1-881 of SEQ ID NO:2. 4. A recombinant DNA vector comprising a polynucleotide that encodes an AMPA-binding human GluR4B receptor having the sequence of amino acid residues 1-881 of SEQ ID NO:2. 8. A mammalian cell genetically engineered to produce GluR4B receptor, said cell containing a heterologous polynucleotide that encodes an AMPA-binding human GluR4B receptor having the sequence of amino acid residues 1-881 of SEQ ID NO:2. In addition, the Keinanen, McNamara and Sommer ‘90 references relied upon in the present application to support the rejection under 35 U.S.C. § 103 are cited on the face of the ‘785 patent as considered. While the examiner may issue a rejection if appropriate under these circumstances, a rejection using the rationale set forth above would appear to require the signature of the Group Director. Compare MPEP ' 2307.02 (7th ed., July 1998). We note the Group Director did not sign the examiner’s action. Generally, appeals on these facts are remanded to provide the examiner an opportunity to consider the issued patent and determine its effect, if any, on the issues raised under 35 U.S.C. § 103. However, after considering the facts in this 75 We note that the instant application and Serial No. 08/259,164, now the ‘785 patent share the same parent application. The present application is a continuation of Serial No. 08/091,440, which is a divisional of Serial No. 07/924,553. ‘785 issued from application Serial No. 08/259,164 which is a continuation of Serial No. 07/924,553. 101Page: Previous 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 NextLast modified: November 3, 2007